GTC was honored to be featured in the Orange County Business Journal
GTC featured in the Orange County Business Journal on September 30, 2019 [Click image to enlarge]
GTC featured in the Orange County Business Journal on September 30, 2019 [Click image to enlarge]
We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay
MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in
GTC Receives Medicare Coverage for 2 NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms Irvine, California– June 19, 2019 – Genomic Testing
When you order GTC Breast Cancer Profile The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine
The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities
Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019
Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA
CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster
Order GTC Solid Tumor Expression/Fusion Profile Sarcoma Diagnosis and Classification. The GTC Solid Tumor Expression/Fusion Profiling provides highly informative and actionable data for patients with